{"id":89287,"date":"2019-04-07T02:42:35","date_gmt":"2019-04-07T09:42:35","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/04\/gene-therapy-was-hailed-as-a-revolution-then-came-the-bill"},"modified":"2019-04-07T02:42:35","modified_gmt":"2019-04-07T09:42:35","slug":"gene-therapy-was-hailed-as-a-revolution-then-came-the-bill","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/04\/gene-therapy-was-hailed-as-a-revolution-then-came-the-bill","title":{"rendered":"Gene Therapy Was Hailed as a Revolution. Then Came the Bill"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/gene-therapy-was-hailed-as-a-revolution-then-came-the-bill.jpg\"><\/a><\/p>\n<p>More drugmakers are betting gene therapies will have a big impact on patients and profits, with Pfizer Inc. last month agreeing to collaborate with Paris-based Vivet Therapeutics on a treatment for a rare liver disorder. The U.S. Food and Drug Administration forecasts as many as 20 cell- and gene-therapy approvals each year by 2025. Doubts remain about whether the treatments will sustain their dramatic results, making it difficult to determine their value.<\/p>\n<hr>\n<p>Dozens of revolutionary gene therapies that mend faulty strands of DNA are on their way, bringing the power to eliminate lethal childhood diseases, rare blood disorders and other severe illnesses.<\/p>\n<p>Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.<\/p>\n<p>The new therapies aim to fix the root causes of disease with a single dose, and if they can replace a lifetime of conventional costly drugs, they may slash overall spending, even at multimillion-dollar prices. Yet the prospect of high costs is already stirring pushback.<\/p>\n<p><a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2019-04-07\/gene-therapy-was-hailed-as-a-revolution-then-came-the-bill\" target=\"_blank\" rel=\"noopener noreferrer\"><\/p>\n<div style=\"clear:both;\">Read more<\/div>\n<p><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>More drugmakers are betting gene therapies will have a big impact on patients and profits, with Pfizer Inc. last month agreeing to collaborate with Paris-based Vivet Therapeutics on a treatment for a rare liver disorder. The U.S. Food and Drug Administration forecasts as many as 20 cell- and gene-therapy approvals each year by 2025. Doubts [\u2026]<\/p>\n","protected":false},"author":417,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-89287","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/89287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/417"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=89287"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/89287\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=89287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=89287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=89287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}